Plain English coverage of UK weight loss injections including Mounjaro, Wegovy and Ozempic — how they work, NHS access, private clinic costs and real patient experiences.
Results emerging from retatrutide’s clinical development programme have generated significant excitement, with some reports suggesting the drug could outperform tirzepatide — sold in the UK as Mounjaro — for weight loss. The figures being quoted are striking. But there is an important catch: this is not yet a true head-to-head comparison. Retatrutide and Mounjaro have…
Three million UK adults are now estimated to use GLP-1 medicines, according to new analysis from PwC — a figure that shows just how rapidly treatments such as Mounjaro and Wegovy have moved into the mainstream. The scale of the GLP-1 revolution in the UK is coming into sharper focus. According to analysis reported by…
For several years, people taking weight-loss medicines such as semaglutide (Ozempic, Wegovy) have been reporting something unexpected: they seem to want alcohol less. The drinks they used to enjoy feel less appealing. Some describe losing interest in alcohol almost entirely. Scientists have been trying to work out whether this is real, and if so, why….
If you have been following the weight loss medicine story closely, you will have noticed that retatrutide and Mounjaro keep appearing in the same conversation. Both are made by Eli Lilly. Both act on GLP-1 receptors. And early trial data for retatrutide suggests it may produce greater weight loss than Mounjaro. But the two medicines…
A comparison that would have seemed far-fetched a few years ago is now being made with increasing seriousness by doctors: that retatrutide, a next-generation weight-loss medicine currently in late-stage clinical trials, is starting to follow a trajectory similar to anabolic steroids — sought and self-administered by people in the fitness world for body-composition goals, well…
Grey market retatrutide is at the centre of a serious and urgent conversation across weight loss medication communities this week. Six cases of acute liver toxicity — meaning sudden, significant damage to the liver — have been reported in patients who injected products labelled as retatrutide since January 2026. The products were purchased online and…
When the Pharmaceutical Journal reported this week that 3.3 million UK adults are expected to use weight loss jabs in 2026, it marked a genuine turning point. This is no longer a niche private treatment for early adopters. It is becoming one of the most widely used drug classes in modern British medicine. But scale…
A new injectable weight loss medicine called CagriSema UK is generating serious attention among doctors and patients alike. Developed by Novo Nordisk — the same company behind Ozempic and Wegovy — it combines two separate drugs into one weekly injection. Early clinical trial results suggest it could help people lose significantly more weight than any…
If you have heard about weight loss jabs from a friend, seen them on the news, or quietly Googled them at midnight, you are not alone. Millions of UK women are asking the same question right now: is Mounjaro or Ozempic the better choice for me? This development was announced on 1 January 2025, as…
The NHS Mounjaro rollout has entered a significant new phase in England, expanding access to tirzepatide — the active ingredient in Mounjaro — to a broader group of patients. This development was announced on June 2026. According to NHS England and GOV.UK, patients with a BMI of 35 or above who also have at least…